→ Novartis’ eye care business Alcon — being spun off by the Swiss drugmaker — will start trading on the Swiss market and NYSE on April 9. Alcon was purchased by former Novartis chairman Daniel Vasella for $51.6 billion, but the unit’s underwhelming performance had begun to weigh on Novartis $NVS, prompting newly approved chief Vas Narasimhan to make the decision to offload it last year.
→ On Wednesday, Novo Nordisk $NVO submitted a US marketing application for potential blockbuster oral GLP-1, semaglutide, a critical component of the Danish drugmaker’s long-term growth strategy. As promised, the world’s top diabetes drugmaker has used a priority voucher to hasten the FDA review process to six months, versus the standard ten. Separately, an NDA was submitted for oral semaglutide’ use in reducing CV risk in type 2 diabetics, but this application will be subject to the standard ten-month review.
Oral semaglutide (GLP1R agonist) for diabetes (now) and for obesity (in near future) is IMO most exciting therapeutic option(s) in near future for cardiometabolic disease!
Novo Nordisk submits diabetes pill for U.S. approval https://t.co/SYpHIBp74c
— Sek Kathiresan MD (@skathire) March 21, 2019
→ Australian biotech Immutep has been granted a new US patent, as part of a continuation application following the grant of the parent patent issued in February 2017, it said on Thursday. This new patent provides IP protection for Immutep’s method of treating cancer by the administration of a chemotherapy agent, and a plurality of doses of its experimental drug, eftilagimod alpha — used to generate a monocyte mediated immune response. Shares of drug developer $IMMP shot up more than 47% to $3.30 premarket.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription